Pneumopathies dites atypiques à coronavirus

A new respiratory illness, designated as atypical pneumonia, produces in 20% of the cases a much more serious disease termed severe acute respiratory syndrome (SARS), which can be fatal in 5% of the cases. Delayed diagnosis and treatment are the underlying causes for the development of SARS. Measure...

Descripción completa

Detalles Bibliográficos
Autor principal: Pariente, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Éditions scientifiques et médicales Elsevier SAS. 2004
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147149/
http://dx.doi.org/10.1016/j.emcpn.2003.11.001
_version_ 1783520361916137472
author Pariente, R
author_facet Pariente, R
author_sort Pariente, R
collection PubMed
description A new respiratory illness, designated as atypical pneumonia, produces in 20% of the cases a much more serious disease termed severe acute respiratory syndrome (SARS), which can be fatal in 5% of the cases. Delayed diagnosis and treatment are the underlying causes for the development of SARS. Measures for the management of the disease should be taken swiftly, based on clinical symptoms, definite contact and isolation of the virus. Current treatment of SARS involves antiviral agents, such as ribavirin, and corticosteroids.
format Online
Article
Text
id pubmed-7147149
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Éditions scientifiques et médicales Elsevier SAS.
record_format MEDLINE/PubMed
spelling pubmed-71471492020-04-10 Pneumopathies dites atypiques à coronavirus Pariente, R EMC - Pneumologie Article A new respiratory illness, designated as atypical pneumonia, produces in 20% of the cases a much more serious disease termed severe acute respiratory syndrome (SARS), which can be fatal in 5% of the cases. Delayed diagnosis and treatment are the underlying causes for the development of SARS. Measures for the management of the disease should be taken swiftly, based on clinical symptoms, definite contact and isolation of the virus. Current treatment of SARS involves antiviral agents, such as ribavirin, and corticosteroids. Éditions scientifiques et médicales Elsevier SAS. 2004-01 2004-05-27 /pmc/articles/PMC7147149/ http://dx.doi.org/10.1016/j.emcpn.2003.11.001 Text en Copyright © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pariente, R
Pneumopathies dites atypiques à coronavirus
title Pneumopathies dites atypiques à coronavirus
title_full Pneumopathies dites atypiques à coronavirus
title_fullStr Pneumopathies dites atypiques à coronavirus
title_full_unstemmed Pneumopathies dites atypiques à coronavirus
title_short Pneumopathies dites atypiques à coronavirus
title_sort pneumopathies dites atypiques à coronavirus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147149/
http://dx.doi.org/10.1016/j.emcpn.2003.11.001
work_keys_str_mv AT parienter pneumopathiesditesatypiquesacoronavirus

Ejemplares similares